| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.bdhind.com | |
| Market Cap | 71.10 Cr. | |
| Enterprise Value(EV) | 55.80 Cr. | 2021-09 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | 12.49 | Trailing Twelve Months Ending 2021-12 |
| Price-Earning Ratio (PE) | 9.89 | Trailing Twelve Months Ending 2021-12 |
| Industry PE | 29.26 | Trailing Twelve Months Ending 2021-12 |
| Book Value / Share | 78.73 | Trailing Twelve Months Ending 2021-12 |
| Price to Book Value | 1.57 | Calculated using Price: 123.50 |
| Dividend Yield | 2.43 | Period Ending 2021-03 |
| No. of Shares Subscribed | 0.58 Cr. | 5,757,300 Shares |
| FaceValue | 10 | |
| Company Profile | ||
|
BDH Industries was incorporated on December 5, 1990 and was converted into a public limited company on April 29, 1994. BDH Industries is engaged in the manufacture and marketing of formulations and bulk drugs. It is today recognised as one of India's leading manufacturers of therapeutic formulations covering wide range of pharmaceuticals. BDH exports a wide range of finished pharmaceutical formulations and bulk drugs to leading organizations in several countries, including Australia, Bolivia, Denmark, Dominican Republic, Germany, Ghana, Japan, Kenya, Madagascar, Malaysia, Mozambique, Netherlands, Niger, Nigeria, Papua New Guinea, Yemen, Singapore, Sri Lanka, Sudan, West Indies, Zambia, Zimbabwe, etc. Products offered by the Company: Some of its therapeutical categories are: 1. Anti-cancer 2. Antibiotics & Anti-microbials 3. Cardiovascular 4. Psychotropic 5. External Preparations 6. Sterile Opthalmics Preparations 7. Generics & Branded Generics 8. Injectables It also manufactures sildenafil citrate tablets for male impotency Achievements:
|
||
Company Profile
BDH Industries was incorporated on December 5, 1990 and was converted into a public limited company on April 29, 1994.
BDH Industries is engaged in the manufacture and marketing of formulations and bulk drugs. It is today recognised as one of India's leading manufacturers of therapeutic formulations covering wide range of pharmaceuticals.
BDH exports a wide range of finished pharmaceutical formulations and bulk drugs to leading organizations in several countries, including Australia, Bolivia, Denmark, Dominican Republic, Germany, Ghana, Japan, Kenya, Madagascar, Malaysia, Mozambique, Netherlands, Niger, Nigeria, Papua New Guinea, Yemen, Singapore, Sri Lanka, Sudan, West Indies, Zambia, Zimbabwe, etc.
Products offered by the Company:
Some of its therapeutical categories are:
1. Anti-cancer 2. Antibiotics & Anti-microbials 3. Cardiovascular 4. Psychotropic 5. External Preparations 6. Sterile Opthalmics Preparations 7. Generics & Branded Generics 8. Injectables
It also manufactures sildenafil citrate tablets for male impotency
Achievements:
| 1 Day |
|
+1.35% |
| 1 Week |
|
+1.23% |
| 1 Month |
|
-13.33% |
| 3 Month |
|
-12.69% |
| 6 Month |
|
+0.98% |
| 1 Year |
|
+26.47% |
| 2 Year |
|
+108.79% |
| 5 Year |
|
+47.11% |
| 10 Year |
|
+671.88% |
| 9 years | 2013-03 | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | |
| Return on Equity (%) | 8.49 | 11.02 | 11.69 | 13.40 | 12.51 | 13.13 | 15.46 | 17.11 | 16.26 | |
| Return on Capital Employed (%) | 12.36 | 13.55 | 13.25 | 15.39 | 14.90 | 14.74 | 16.94 | 19.14 | 18.74 | |
| Return on Assets (%) | 4.39 | 5.11 | 5.15 | 6.23 | 6.27 | 6.77 | 7.88 | 9.08 | 9.35 |
| Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2021-09* Rs. Cr. |
| Shh. Funds | 22 | 23 | 24 | 27 | 29 | 31 | 34 | 38 | 43 | 45 | |
| Non Curr. Liab. | 1 | 1 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 1 | |
| Curr. Liab. | 19 | 24 | 27 | 24 | 23 | 24 | 30 | 26 | 27 | 25 | |
| Minority Int. | |||||||||||
| Equity & Liab. | 42 | 48 | 52 | 52 | 54 | 57 | 66 | 65 | 71 | 70 | |
| Non Curr. Assets | 15 | 15 | 13 | 17 | 23 | 23 | 22 | 21 | 20 | 20 | |
| Curr. Assets | 27 | 33 | 38 | 35 | 31 | 34 | 44 | 44 | 51 | 50 | |
| Misc. Exp. not W/O | |||||||||||
| Total Assets | 42 | 48 | 52 | 52 | 54 | 57 | 66 | 65 | 71 | 70 |
| Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2021-12 Rs. Cr. TTM |
| Net Sales | 41 | 43 | 45 | 46 | 44 | 41 | 52 | 59 | 57 | 71 | |
| Other Income | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | |
| Total Income | 41 | 44 | 46 | 48 | 45 | 42 | 53 | 60 | 59 | 72 | |
| Total Expenditure | -37 | -39 | -41 | -42 | -39 | -36 | -45 | -51 | -49 | -61 | |
| PBIDT | 4 | 5 | 5 | 6 | 6 | 6 | 8 | 10 | 10 | 11 | |
| Interest | -1 | -1 | 0 | 0 | 0 | 0 | -1 | -1 | 0 | 0 | |
| Depreciation | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | |
| Taxation | -1 | -1 | -1 | -2 | -2 | -1 | -2 | -2 | -2 | -3 | |
| Exceptional Items | |||||||||||
| PAT | 2 | 2 | 3 | 3 | 3 | 4 | 5 | 6 | 6 | 7 | |
| Adjusted EPS | 3 | 4 | 4 | 6 | 6 | 7 | 8 | 10 | 11 | 12 |
| Particulars | 10 years | 2012-03 Rs. Cr. | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. |
| Cash Fr. Operatn. | 9 | 5 | 4 | 6 | 4 | 7 | 0 | -4 | 11 | 1 | |
| Cash Fr. Inv. | 0 | -1 | 0 | 0 | -5 | -5 | 0 | 1 | 1 | 1 | |
| Cash Fr. Finan. | -3 | 1 | 3 | -3 | -1 | -3 | -3 | 3 | -6 | -2 | |
| Net Change | 5 | 6 | 6 | 3 | -1 | -1 | -2 | 0 | 6 | 0 | |
| Cash & Cash Eqvt | 6 | 12 | 18 | 21 | 20 | 19 | 17 | 17 | 23 | 23 |
|
Wed, 18 May 2022
Board Meeting Intimation for Considering And Approving The Audited Standalone Financial Results For The Fourth Quarter And Financial Year Ended On 31St March 2022 And Recommendation Of Dividend If Any For The Financial Year Ended On 31St March 2022. BDH INDUSTRIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/05/2022 inter alia to consider and approve the Audited Standalone Financial Results for the fourth quarter and financial year ended on 31st March 2022 and Recommendation of dividend if any for the financial year ended on 31st March 2022. |
|||||||||||||||||||||
|
Wed, 27 Apr 2022
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A Format of Initial Disclosure to be made by an entity identified as a Large Corporate.
We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No Name of the Company Secretary: Ms NIKITA PHATAK Designation: COMPANY SECRETARY EmailId: comp.sec@bdhind.com Name of the Chief Financial Officer: Mr S C KACHHARA Designation: CHIEF FINANCIAL OFFICER EmailId: info@bdhind.com Date: 27/04/2022 Note: In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. |
|||||||||||||||||||||
|
Sat, 16 Apr 2022
Certificate Under Regulation 40(9) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 Certificate under Regulation 40(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 is enclosed herewith. |
| Fri, 20 May 2022 |
High Delivery Percentage
|
Higher Delivery Quantity
|
Higher Delivery Quantity and Percentage
|
Higher Trade Quantity
|
Higher Trade and Delivery Quantity
|
Equities
M.F.
Sectors